Caprion Will Use CellCarta to Help Vertex Pharma Discover Biomarkers

Vertex Pharmaceuticals will rely on data from Caprion Pharmaceuticals' CellCarta proteomics platform as part of a biomarker-discovery collaboration, Caprion said this week.

As part of the deal, Caprion will identify potential pharmacodynamic biomarkers in samples from certain clinical and pre-clinical studies conducted by Vertex.

Caprion's platform profiles proteins and provides protein expression and identification in tissues and blood plasma.